Skip to main content
. Author manuscript; available in PMC: 2022 Dec 6.
Published in final edited form as: Int J Hyperthermia. 2022;39(1):855–864. doi: 10.1080/02656736.2022.2097323

Table 4.

Genes with statistically significant expression changes post HIFU, in the Soft Tissue Sarcoma group.

Symbol Description Fold change p-value
CD3E CD3e molecule, epsilon (CD3-TCR complex)  11.3929 .011236
CD3D CD3d molecule, delta (CD3-TCR complex)  10.925 .011583
DLA-DOB major histocompatibility complex, class II, DO beta    9.56251 .007551
CCL21 chemokine (C-C motif) ligand 21    8.92264 .021212
TRBC    7.90738 .013974
CD22 CD22 molecule    7.8532 .013559
CD3G CD3g molecule, gamma (CD3-TCR complex)    7.32257 .017454
TCF7 transcription factor 7 (T-cell specific, HMG-box)    6.69229 .015112
SLAMF6 SLAM family member 6    6.11109 .024896
CR1L    6.07894 .031854
SELE selectin E    5.95124 .014139
IL2RG interleukin 2 receptor, gamma    5.35498 .044532
TOX thymocyte selection-associated high mobility group box    5.32352 .003619
LCK lymphocyte-specific protein tyrosine kinase    5.12961 .014522
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11    4.78822 .040326
CDH1 cadherin 1, type 1, E-cadherin (epithelial)    4.27929 .048927
TNFRSF13C tumor necrosis factor receptor superfamily, member 13C    4.19875 .014028
CYFIP2 cytoplasmic FMR1 interacting protein 2    4.13925 .010465
S100A8 S100 calcium binding protein A8    3.64829 .037835
LOC100049001 tryptase    3.11392 .027965
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)    2.92106 .009146
GH1 growth hormone    2.87671 .00263
LOC477699    2.53728 .045067
NT5E 5′-nucleotidase, ecto (CD73)    2.42019 .043786
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog    2.22728 .014551
ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1    2.15832 .039782
VEGFA vascular endothelial growth factor A  −3.06498 .010696
PLAUR plasminogen activator, urokinase receptor  −3.71592 .045821

Mean fold change in gene expression following HIFU treatment compared with baseline, normalized using housekeeping controls is presented.